Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
HCW Biologics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
HCWB
Nasdaq
2836
www.hcwbiologics.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for HCW Biologics Inc.
HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
- Nov 19th, 2025 6:30 am
HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease
- Nov 18th, 2025 5:25 am
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results
- Nov 14th, 2025 2:44 pm
HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer
- Nov 10th, 2025 5:00 am
HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
- Nov 7th, 2025 5:00 am
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment
- Oct 22nd, 2025 7:00 am
HCW Biologics to Participate in the 2025 Maxim Growth Summit
- Oct 16th, 2025 7:25 am
HCW Biologics’ Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer
- Oct 16th, 2025 7:15 am
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program
- Sep 30th, 2025 6:45 am
HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing
- Sep 18th, 2025 7:15 am
HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development
- Sep 16th, 2025 6:00 am
Wall Street Set to Open Little Changed Friday Ahead of Consumer Sentiment Report
- Sep 12th, 2025 7:21 am
Consumer Sentiment, Oil Inventory Reports Set for Release as US Futures Little Changed in Friday's Premarket Session
- Sep 12th, 2025 6:03 am
HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program
- Sep 9th, 2025 6:00 am
BC-Most Active Stocks
- Aug 25th, 2025 8:30 am
HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market
- Aug 25th, 2025 6:00 am
HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results
- Aug 18th, 2025 12:44 pm
HCW Biologics Second Quarter 2025 Earnings: US$0.90 loss per share (vs US$16.16 loss in 2Q 2024)
- Aug 16th, 2025 6:18 am
Insiders Re-Evaluate Their US$3.05m Stock Purchase As HCW Biologics Falls To US$6.9m
- Jul 2nd, 2025 8:27 am
HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors
- Jun 27th, 2025 5:45 am
Scroll